PrognomiQ Announces Breakthrough Results for Early Lung Cancer Detection

PrognomiQ announced early results from its ProVue Lung test, a blood-based diagnostic aimed at early lung cancer detection in high-risk individuals. The test showed an 89% sensitivity for detecting lung cancer, with a significant portion being Stage I. The findings suggest a potential enhancement to current standard care methods, particularly given the barriers many high-risk individuals face with traditional low-dose CT screening.